RENMAB
LIVE

Serial Number

88985441

Owner

Beijing Biocytogen Co., Ltd.

Attorney

Cynthia Johnson Walden

Filing Date

Jul 31, 2019

Add to watchlist:

No watchlists yet
View on USPTO

RENMAB Trademark

Serial Number: 88985441 • Registration: 8026774

RENMAB is a trademark filed by Beijing Biocytogen Co., Ltd. on July 31, 2019. The trademark is classified under Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 31 (Natural Agricultural Products). The application is currently registered and active.

Owner Contact Info

Beijing Biocytogen Co., Ltd. (6 trademarks)

88 Kechuang 6th Ave, BDA
Beijing 100176 , CN

Entity Type: 99

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO. (2 trademarks)

No. 12 Baoshen South Street
Daxing District, Beijing 102609 , CN

Entity Type: 99

Trademark Details

Filing Date

July 31, 2019

Registration Date

November 18, 2025

Published for Opposition

August 17, 2021

Goods & Services

(Based on 44(e)) Live experimental animal; live animals; live poultry; live hamster; live swine; living trees; plant seeds; hay; living plants

(Based on 44(e)) Chemical additives for insecticides; nitrogen fertilizer; food preservative chemicals; biological preparations not for medical or veterinary use; radioactive elements for scientific purposes; diagnostic preparations not for medical or veterinary use; protein in raw material form for scientific and medical research, and industrial use; plasticizers being industrial chemicals; industrial adhesives; industrial chemicals, not for medical use

(Based on 44(e)) Drug development services for others provided via a platform for antibody discovery that features experimental animal research; drug evaluations being pharmaceutical research provided via a platform for antibody discovery that features experimental animal research; pharmaceutical research provided via a platform for antibody discovery that features experimental animal research; Implementation of early assessment in new drug development fields for others, involving experimental animals, to support the development by others of pharmaceutical preparations and medicines; development of pharmaceutical preparations and medicines provided via a platform for antibody discovery that features experimental animal research; clinical trials being pharmaceutical and scientific research services provided via a platform for antibody discovery that features experimental animal research; package design; research and development of antibodies provided via a platform for antibody discovery that features experimental animal research; research and development of new products for others provided via a platform for antibody discovery that features experimental animal research; products development for others provided via a platform for antibody discovery that features experimental animal research; consulting services in biotechnology development fields involving experimental animal research and antibodies discovered from the same, the aforementioned also provided via a platform for antibody discovery that features experimental animal research; biological research and analyses provided via a platform for antibody discovery that features experimental animal research; biochemistry research and analyses provided via a platform for antibody discovery that features experimental animal research; biotechnology research provided via a platform for antibody discovery that features experimental animal research

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 18, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 18, 2025 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Oct 27, 2025 DP1B
NOTICE OF ALLOWANCE CANCELLED
Oct 27, 2025 IUCN
DIVISIONAL PROCESSING COMPLETE
Oct 27, 2025 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 23, 2025 AITU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 2, 2025 EXRA
SOU EXTENSION 1 GRANTED
Oct 1, 2025 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 1, 2025 AITU
SOU TEAS EXTENSION RECEIVED
May 19, 2025 EEXT
DIVISIONAL REQUEST RECEIVED
May 18, 2025 DRRR
SOU EXTENSION 1 FILED
May 18, 2025 EXT1
TEAS REQUEST TO DIVIDE RECEIVED
May 18, 2025 ERTD
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 13, 2025 CHAN
TEAS POST PUBLICATION AMENDMENT RECEIVED
May 1, 2025 EPPA
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 19, 2024 NOAM
TTAB RELEASE CASE TO TRADEMARKS
Oct 21, 2024 TMBN
OPPOSITION TERMINATED NO. 999999
Oct 21, 2024 OP.T
OPPOSITION DISMISSED NO. 999999
Oct 21, 2024 OP.D
OPPOSITION INSTITUTED NO. 999999
Feb 14, 2022 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Sep 15, 2021 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 17, 2021 NPUB
PUBLISHED FOR OPPOSITION
Aug 17, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 28, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 9, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 9, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 9, 2021 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jul 6, 2021 ERSI
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 17, 2021 ASGN
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 5, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 5, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 5, 2021 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 2, 2020 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 29, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
May 29, 2020 GNSL
SUSPENSION LETTER WRITTEN
May 29, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 12, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 12, 2020 CRFA
ASSIGNED TO LIE
May 8, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 5, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 5, 2019 GNRN
NON-FINAL ACTION E-MAILED
Nov 5, 2019 GNRT
NON-FINAL ACTION WRITTEN
Nov 5, 2019 CNRT
ASSIGNED TO EXAMINER
Oct 28, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 14, 2019 NWOS
NEW APPLICATION ENTERED
Aug 3, 2019 NWAP